hVIVO PLC
LSE:HVO

Watchlist Manager
hVIVO PLC Logo
hVIVO PLC
LSE:HVO
Watchlist
Price: 22 GBX -3.93% Market Closed
Market Cap: 149.7m GBX
Have any thoughts about
hVIVO PLC?
Write Note

hVIVO PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

hVIVO PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
hVIVO PLC
LSE:HVO
Additional Paid In Capital
ÂŁ516k
CAGR 3-Years
N/A
CAGR 5-Years
-49%
CAGR 10-Years
-19%
Oxford Nanopore Technologies PLC
LSE:ONT
Additional Paid In Capital
ÂŁ698.6m
CAGR 3-Years
5%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Additional Paid In Capital
ÂŁ37.1m
CAGR 3-Years
0%
CAGR 5-Years
227%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Additional Paid In Capital
ÂŁ54.3m
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
11%
Ergomed PLC
LSE:ERGO
Additional Paid In Capital
ÂŁ1m
CAGR 3-Years
-67%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Additional Paid In Capital
ÂŁ58.5m
CAGR 3-Years
3%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

hVIVO PLC
Glance View

Market Cap
149.7m GBX
Industry
Life Sciences Tools & Services

hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

HVO Intrinsic Value
26.83 GBX
Undervaluation 18%
Intrinsic Value
Price

See Also

What is hVIVO PLC's Additional Paid In Capital?
Additional Paid In Capital
516k GBP

Based on the financial report for Jun 30, 2024, hVIVO PLC's Additional Paid In Capital amounts to 516k GBP.

What is hVIVO PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
-19%

Over the last year, the Additional Paid In Capital growth was 20%.

Back to Top